Chemotherapy of disseminated germ cell tumors

World Journal of Urology

Volumn 19, Issue 2, 2001, Pages 82-89

  Nichols, Craig R ^a   Nichols, C R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEP PROTOCOL; BLEOMYCIN; CISPLATIN; ETOPOSIDE;

CANCER STAGING; GERM CELL TUMOR; HUMAN; MALE; PATHOLOGY; REVIEW; TESTIS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; GERMINOMA; HUMANS; MALE; NEOPLASM STAGING; TESTICULAR NEOPLASMS;

EID: 0035318726     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450000188     Document Type: Article

References (30)

1. Shibley L, Brown M, Schuttinga J et at (1990) Cisplatin-based combination chemotherapy in the treatment of advanced-stage testicular cancer: cost-benefit analysis. J Natl Cancer Inst 82: 186-192
2. Donohue J, Thornhill JA, Foster RS et al (1995) Role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: Indiana University experience (1965-1989) J Urol 153' 85-89
3. Richie J, Kantoff P (1991) Is adjuvant chemotherapy necessary for patients with stage Bl testicular cancer? J Clin Oncol 9' 1393
4. Williams S, et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 317: 1433-1438
5. Motzer R, Sheinfeld J, Mazumdar M et al (1995) Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 13: 2700-2704
6. Nichols C, Gonin R, Foster R (1995) Defining new standards for adjuvant therapy of testis cancer. J Clin Oncol 13: 26812683
7. Behnia M, Foster R, Roth BJ et al (1996) Adjuvant bleomycin, etoposide, and cisplatin in fully resected stage B nonseminomatous testicular cancer. Proc Am Soc Clin Oncol 14
8. Peckham M, McElwain M (1974) Radiotherapy of testicular tumors. Proc R Soc Med 67: 300-303
9. International Germ Cell Consensus Classification (TIGCCC) (1997) A prognostic factor-based staging system for germ cell cancers. J Clin Oncol 15: 594-603
10. Einhorn LH, Williams SD, Loehrer PJ et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7: 387-391
11. Bosl G, Geller NL, Bajorin D et al (1988) A randomized trial of etoposide plus cisplatin versus vinblastine plus bleomycin plus cisplatin plus cyclophosphamide plus dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6: 1231-1238
12. Levi J, Raghavan D, Harvey V et al (1993) The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma. J Clin Oncol 11: 1300-1305
13. Loehrer-PJ S, Johnson D, Elson P et al (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trail. J Clin Oncol 13: 47076
14. de WR, Stoter G, Kaye SB et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group [see comments]. J Clin Oncol 15: 1837-1843
15. Bajorin D, Sarosdy MF, Poster DG (1993) A randomized trial of etoposide + cisplatin vs etoposide carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. JClinOncol 11: 598-606
16. Horwich A, Sleijfer DT, Fossa SD (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatice. Multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J ClinOncol, 15: 1844-1852
17. de Wit R et al (2000) Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles and the 5 day schedule vs 3 days per cyle in good prognosis germ cell cancer. AN EORTC/MRC phase III study. Proc Am Soc Clin Oncol 19: 326a
18. Williams S, Birch R, Einhorn LH et al (1987) Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med 316: 1435-1440
19. Ozols RF, Ihde DC, Linehan WM et al (1988) A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031-1040
20. Nichols C, Williams SD, Loehrer PJ et al (1991) Randomized study of cisplatin dose intensity in advanced germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163-1172
21. Nichols C, Catalano PJ, Crawford ED et al (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 16: 1287- 1293
22. Kaye S, Mead GM, Fossa SD et al (1998) Intensive-induction sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692-701
23. Blanke C, Loehrer P, Einhorn L et al (1994) A phase II trial of VP-16 plus ifosfamide plus cisplatin plus vinblastine plus bleomycin (VIP/VB) with filgrastim for advanced stage testicular cancer. Proc Am Soc Clin Oncol 13: 234
24. Bokemeyer C, Kollmannsberger C, Meisner C et al (1999) First-line high-dose chemotherapy (HD-CT) versus standarddose PEB/PEI (SD-CT) in patients with advanced germ cell tumors (GCT). A matched pair analysis. Proc Am Soc Clin Oncol 17: 3450-3456
25. Amato R, Hutchinson L, Striegel A (1994) Modulation of dose intensity(DI) by reducing chemotherapy (CHT) intervals in patients with high volume non-seminomatous germ cell tumors (HV-GCT). Proc Am Soc Clin Oncol 13: 253
26. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1995) Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153 (3 Pt 2): 976-980
27. Fox E, Weathers TD, Williams SD et al (1993) Outcome analysis for patients with persistent germ cell carcinoma in post chemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11: 1294-1299
28. Motzer R, Bosl G, Heelan R et al (1987) Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 5: 10641070
29. Friedman E, Garnick MB, Stomper PC et al (1985) Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 3: 1325-1332
30. Schultz S, Einhorn LH, Conces-DJ J et al (1989) Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 7: 1497-1503